Current Edition

Argenx

Argenx, already deep into its Vyvgart launch, charts course to become immunology ‘powerhouse’: CEO

Argenx is off to the races with the launch of its new med Vyvgart. With its first FDA-approved drug Vyvgart now rolling out, Argenx is …

Continue Reading →
Dupixent

Sanofi and Regeneron’s Dupixent aces another test, this time in the debilitating itch condition prurigo nodularis

Sanofi and Regeneron have big ambitions for immunology superstar Dupixent—envisioning the potential for $11 billion in annual sales. In acing a test in people with …

Continue Reading →
cancer

Nanobiotix presented new clinical and pre-clinical data confirming NBTXR3’s significant potential role in Immuno-Oncology at SITC Annual Meeting

Nanobiotix, a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, recently presented positive clinical and preclinical data from the ongoing immuno-oncology programs. …

Continue Reading →